Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells

Chu, Shao‐Yin; Liu, Yue-wang; Zhang, Li; Liu, Bei; Li, Li; Shi, Jun-zhen

doi:10.1007/s11033-012-1930-3

Cited by 42 publications

(33 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, HSP90 has been linked to chemoresistance in different clinical settings including breast cancer [36][37][38][39][40][41].The described study of Song et al [29] corroborates the observations that low HSP90 expression is a positive prognostic feature. In our study we pinpointed the predictive aspect of the association of HSP90 with proliferation markers and its association with the higher response to chemotherapy.…”

Section: Discussionsupporting

confidence: 66%

Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy

Jarząb

Kowal

Bal

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Introduction. Prediction of response to preoperative breast cancer chemotherapy may offer a substantial optimization of medical management of this disease. The most efficient prediction would be done a priori, before the start of chemotherapy and based on the biological features of patient and tumor. Numerous markers have been proposed but none of them has been applied as a routine. The role of MKI67 and HSP90 expression has been recently suggested to predict treatment sensitivity in HER2-positive breast cancer. The aim of this study was to validate the utility of proliferation based markers (MKI67 and CDK1) and heat shock proteins (namely HSP90) to predict response to chemotherapy in cohort of breast cancer patients treated preoperatively. Material and methods. Ninety-three patients with breast cancer, all females, mean age 42.2 years, among them 32% T1-T2 patients, 49% T3 patients and 13% with T4 tumor stage, 27% N0, 42% N1, 16% N2, 15% N3 were subjected to initial chemotherapy. The majority of patients (86%) received anthracycline and taxane chemotherapy. Among the patients there were 9 individuals with metastatic disease (M1) at initial presentation, and 11 patients were not treated surgically after initial chemotherapy (no sufficient disease response). From 82 patients operated on, 20 patients (24%) showed pathological complete response (pCR), while in 62 patients there was Results. There were no statistically significant differences in MKI67 and CDK1 expression between pCR and no pCR groups (p = 0.099 and 0.35, respectively), although the median expression of both genes was slightly higher in pCR group. In contrast, both HSP90AA1 and HSP90AB1 transcripts showed decreased expression in pCR group (medians 0.77 and 0.55) when compared to no pCR group (median 0.86 and 0.73), statistically significant for HSP90AA1 (p = 0.031) and of borderline significance for HSP90AB1 (p = 0.054). The most significant predictor of pCR was the ratio of CDK1 transcript to HSP90AA transcript. This ratio was significantly higher in CR group (median 0.99) than in no CR group (median 0.68, p = 0.0023), and showed a potential diagnostic utility (area under receiver operating characteristic [ROC] curve 0.72). Conclusions. HSP90AA1 and AB1 genes exhibit low expression in breast cancers highly sensitive to chemotherapy and may indicate the patients with higher probability of pathological complete response. The ratio of HSP90AA1 to proliferation-related markers (CDK1 or MKI67) may be even better predictor of pCR chance, with higher expression of proliferation genes and lower stress response in patients sensitive to chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 66%

Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy

Jarząb

Kowal

Bal

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Two investigators (Yifan Sun and Shan Li) assessed the quality of the selected studies independently, following the criteria predefined by Thakkinstian et al [ 18 ] and used by Ye et al [ 19 ]( S1 Table ). The criteria were the sources of the cases and controls, the total sample size, the source of the specimens, and the HWE of the controls.…”

Section: Methodsmentioning

confidence: 99%

Interferon Gamma +874T/A Polymorphism Increases the Risk of Hepatitis Virus-Related Diseases: Evidence from a Meta-Analysis

Sun

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

BackgroundInterferon gamma (IFN-γ) is a key regulatory cytokine, which plays an important role in antiviral defense of an infected host. However, the association between the IFN-γ +874T/A gene polymorphism and hepatitis virus-related diseases is heterogeneous.MethodsBased on the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, a comprehensive literature search of eligible studies in Embase, Pubmed, and the Cochrane Library was undertaken through November 2014. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were used to measure the strength of the models.ResultsSeventeen case-control articles, including 24 studies with 5503 individuals, met the inclusion criteria. The results indicated a statistically significant association between the IFN-γ +874T/A polymorphism and hepatitis virus—related diseases in a recessive gene model (AA vs. TT+TA: OR=1.350, 95% CI=1.101-1.657, P=0.004, I2%=54.3, and PQ=0.001 for heterogeneity), especially in Asians (OR=1.407, 95% CI=1.035-1.911, P=0.029, I2%=61.9, and PQ=0.005 for heterogeneity) and hepatitis B virus (HBV)–related disease (OR=1.486, 95% CI=1.195–1.849, P=0.000, I2%=40.4, and PQ=0.053 for heterogeneity).ConclusionsThe evidence suggests that the IFN-γ +874T/A polymorphism increases the risk of hepatitis virus—related diseases, especially in Asians and HBV—related diseases. Further studies on this topic in different ethnicities, especially genome-wide association studies, should be conducted to strengthen our results.

show abstract

“…The significant role of HSP90AA1 and HSP90AB1 in several cancer types such as lung cancer, ovarian cancer, and GS is detected and discussed (38)(39)(40). The attenuation role of IL2 in growth of glioma and brain edema in rats is assessed and discussed in details (41).…”

Section: Discussionmentioning

confidence: 99%

Gliosarcoma Protein - Protein Interaction Network Analysis and Gene Ontology

et al. 2018

View full text Add to dashboard Cite

show abstract

Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells

Cited by 42 publications

References 24 publications

Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy

Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy

Interferon Gamma +874T/A Polymorphism Increases the Risk of Hepatitis Virus-Related Diseases: Evidence from a Meta-Analysis

Gliosarcoma Protein - Protein Interaction Network Analysis and Gene Ontology

Contact Info

Product

Resources

About